Glutathione Research: Human Trials, Data & What the Studies Show
Glutathione is a tripeptide antioxidant found in high concentrations in nearly every human cell, especially the liver. The published human literature covers IV infusions, liposomal oral forms and topical delivery — because standard oral glutathione is heavily degraded by digestive enzymes.
Mechanism of action
Glutathione (GSH) is a naturally occurring tripeptide built from glutamate, cysteine and glycine. It is present in high concentrations in almost every cell, with the liver holding the largest reserve.
Its primary research role is redox homeostasis: it neutralises reactive oxygen species, regenerates other antioxidants, and supports phase II detoxification pathways.
Delivery matters. Standard oral glutathione capsules are broken down by intestinal and hepatic enzymes, so the clinical literature focuses on intravenous (IV) infusions, liposomal oral preparations, topical lotions and nebulised applications when the goal is to raise cellular levels.
The studies
Each study below states the benefit that was tested, then what the human data showed. The research-context section at the end explains that many of the strongest findings use IV or liposomal delivery, not conventional oral powder.
Longevity & metabolism
Reversing cellular aging and mitochondrial decay
Benefit tested: can correcting the age-related glutathione deficiency (GshCap) protect mitochondria, lower inflammation and restore physical function in older adults?
Older adults supplemented with GlyNAC — the amino-acid building blocks of glutathione — versus placebo · mitochondrial function, inflammatory markers and physical/cognitive endpoints
- Reversed
- Mitochondrial impairment
- Lowered
- Systemic inflammation (IL-6)
- Improved
- Muscle strength, gait & cognition
Benefits shown in the data
- Correcting glutathione deficiency restored mitochondrial function in older adults.
- Lowered interleukin-6, a key marker of systemic inflammation that rises with age.
- Improved practical outcomes: muscle strength, walking speed and cognitive focus.
- This trial did not give glutathione directly; it supplied glycine and N-acetylcysteine (GlyNAC) so the body could synthesise more of its own glutathione.
- The result links glutathione status to the broader 'GshCap' model of cellular aging.
- Long-term safety and durability of the effect remain active research questions.
Liver health
Treating non-alcoholic fatty liver disease (NAFLD)
Benefit tested: can daily oral glutathione reduce liver enzymes, triglycerides and fat accumulation in people with NAFLD?
NAFLD patients · 300 mg oral glutathione daily · 4 months · ALT, triglycerides and liver fat endpoints
- Significantly reduced
- ALT (liver enzyme)
- Lowered
- Triglycerides
- Decreased
- Liver fat accumulation
Benefits shown in the data
- Reduced alanine aminotransferase (ALT), indicating less ongoing liver-cell injury.
- Lowered triglycerides, a lipid marker tightly linked to fatty liver progression.
- Showed a direct hepatoprotective effect by decreasing physical fat accumulation in liver tissue.
- This was an open-label pilot, so both participants and investigators knew they were receiving glutathione.
- The dose used was 300 mg per day — lower than many IV protocols — yet still produced measurable liver-marker changes.
- Larger randomised trials are needed to confirm the effect size and long-term benefit.
Vascular & mobility
Improving mobility in peripheral artery disease (PAD)
Benefit tested: can daily IV glutathione increase pain-free and maximum walking distance in PAD patients with exercise-induced calf pain?
PAD patients · daily IV glutathione 0.6 g in saline versus placebo · 5 days · treadmill walking distance and inflammatory markers
- Massively increased
- Pain-free walking distance
- Significantly increased
- Maximum walking distance
- Reduced micro-vascular inflammation
- Mechanism driver
Benefits shown in the data
- Dramatically extended how far patients could walk before calf pain forced them to stop.
- Improved maximum walking distance, a functional endpoint that directly affects quality of life.
- Blood tests pointed to reduced micro-vascular inflammation and improved red blood cell flexibility as the mechanism.
- The intervention was intravenous, not oral, so the result cannot be extrapolated to capsules or powders.
- The treatment course was short — 5 days — yet produced a measurable functional benefit.
- This is one of the cleaner vascular human datasets for glutathione, but replication in larger cohorts is still valuable.
Dermatology
Systemic skin lightening and hyperpigmentation correction
Benefit tested: can topical glutathione block tyrosinase, reduce melanin indices and improve skin quality without adverse reactions?
Healthy women · topical 2% glutathione lotion daily · melanin index, wrinkle depth and skin moisture/elasticity endpoints
- Significantly reduced
- Melanin indices
- Minimised
- Wrinkles
- Increased
- Skin moisture & elasticity
Benefits shown in the data
- Blocked tyrosinase, the enzyme that produces melanin, shifting pigment production toward lighter pheomelanin.
- Reduced melanin indices in a statistically significant manner compared with placebo.
- Improved secondary skin-quality markers: fewer wrinkles and better moisture/elasticity, with no adverse skin reactions reported.
- This was a topical 2% lotion, not an oral or IV preparation.
- Skin-lightening is a cosmetic application; the mechanism is the same tyrosinase inhibition studied in dermatology research.
- Long-term safety data for cosmetic use is less extensive than for metabolic indications.
Neurology
Managing symptoms of Parkinson's disease
Benefit tested: can high-dose IV glutathione bypass the gut, enter brain networks and reduce motor disability in Parkinson's patients?
Parkinson's patients · 1,400 mg intravenous glutathione twice daily · 3 consecutive weeks · clinical disability scores
- 42% reduction
- Clinical disability score
- Several months
- Benefit duration
- Substantia nigra glutathione deficiency
- Target deficit
after infusions stopped
Benefits shown in the data
- Produced a 42% reduction in clinical disability scores across the cohort.
- Benefits persisted for up to several months after the 3-week infusion course ended.
- Targets the documented glutathione deficiency in the substantia nigra, the brain region most affected in Parkinson's.
- This was a small pilot trial, not a large randomised controlled study.
- The protocol used high-dose IV glutathione twice daily — a delivery route and schedule that cannot be compared with oral supplementation.
- The persistence of benefit after stopping treatment is promising, but needs confirmation in larger trials.
Storage & handling
Glutathione is supplied as a lyophilised powder. Keep sealed vials refrigerated or frozen, protected from light, moisture and oxygen.
Reconstitute with bacteriostatic water added slowly down the inner wall of the vial; swirl gently until fully dissolved and never shake.
Store reconstituted solution at 2-8 °C, protect from light, and use within your lab's defined stability window. Glutathione oxidises easily, so minimise air exposure and avoid repeated freeze-thaw cycles.
Glutathione research context
Glutathione is one of the most studied endogenous antioxidants. The strongest human data almost always use IV infusion, liposomal encapsulation, or topical application. Conventional oral glutathione powder has poor bioavailability because digestive enzymes break it down before it reaches cells.
Oral bioavailability is limited
Most plain oral glutathione is hydrolysed in the gut and liver. The positive metabolic, vascular and neurological findings above were obtained with IV, liposomal or topical delivery, and should not be assumed to transfer directly to standard oral powder.
IV administration is a clinical procedure
Intravenous glutathione is administered in clinical settings by qualified professionals with appropriate monitoring, consistent with the trials referenced above.
Research-stage, not established therapy
Several of the trials above are pilot or open-label studies. Glutathione is not an approved treatment for Parkinson's disease, PAD, or aging-related decline in South Africa or most jurisdictions.
All information on this page is provided for laboratory and educational reference only. Peptides Lab SA (PTY) Ltd supplies compounds strictly for in-vitro research use. Nothing here is medical advice, a dosing recommendation, or a claim of human safety or efficacy.